Agendia (Huntington Beach, CA and Amsterdam, The Netherlands) has expanded its line of breast cancer genetic profiling tests with BluePrint, a molecular subtyping profile that distinguishes Basal-type, Luminal-type and ERBB2-type (HER2/neu positive) subgroups of tumors. The BluePrint signature determines the RNA levels of 80 genes that best discriminate among these three distinctive subtypes. It is used in combination with the already existing Mammaprint test. Patients with different molecular profiles might have different prognoses with varied responses to specific therapies, so it is expected that in the future the test results could guide therapy decisions.
Press release: Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering…
Product page: Introducing BluePrint: A Molecular Subtyping Profile…
Flashbacks: MammaPrint Identifies Low Risk HER2+ Breast Cancer ; MammaPrint®, a Breast CA Molecular Prognostic Test
BluePrint Identifies Breast Cancer Molecular Subtypes
March 25th, 2010 
Wouter Stomp Genetics, Ob/Gyn, Oncology, Surgery
